Heptavalent botulism antitoxin
| Clinical data | |
|---|---|
| Trade names | BAT |
| Other names | HBAT, H-BAT |
| ATC code |
|
| Legal status | |
| Legal status | |
The Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (trade name BAT), made by Emergent BioSolutions Canada Inc. (formerly Cangene Corporation),[1] is a licensed, commercially available botulism anti-toxin that effectively neutralizes all seven known botulinum nerve toxin serotypes (types A, B, C, D, E, F and G). It is indicated for sporadic cases of life-threatening botulism and is also stockpiled for the eventuality of botulinum nerve toxins being used in a future bioterrorist attack.[2]
BAT was first approved in 2010 by the Centers for Disease Control for the indication of treating naturally occurring non-infant botulism on an investigational basis, replacing two earlier products. It was then licensed for commercial marketing by the United States FDA in 2013.[3]
- ^ "Biological Threats". Emergent BioSolutions. Retrieved September 12, 2017.
- ^ "Botulinum Toxin (Botulism)". Center for Health Security. Retrieved September 12, 2017.
- ^ "INSTRUCTIONS FOR RECEIVING BAT™ ANTITOXIN" (PDF). Alaska Division of Public Health. Archived from the original (PDF) on September 12, 2017. Retrieved January 17, 2022.